Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease.

IF 3.4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Therapeutic Advances in Gastroenterology Pub Date : 2023-10-21 eCollection Date: 2023-01-01 DOI:10.1177/17562848231202159

Reinier Cornelis Anthonius van Linschoten, Anouk Sjoukje Huberts, Nikki van Leeuwen, Jan Antonius Hazelzet, Janneke van der Woude, Rachel Louise West, Desirée van Noord

{"title":"Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease.","authors":"Reinier Cornelis Anthonius van Linschoten, Anouk Sjoukje Huberts, Nikki van Leeuwen, Jan Antonius Hazelzet, Janneke van der Woude, Rachel Louise West, Desirée van Noord","doi":"10.1177/17562848231202159","DOIUrl":null,"url":null,"abstract":"Background: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients.Objectives: We assessed the validity of the SCQ for measuring comorbidities in IBD patients.Design: Cohort study.Methods: We assessed the criterion validity of the SCQ for IBD patients by comparing patient-reported and clinician-reported comorbidities (as noted in the electronic health record) of the 13 diseases of the SCQ using Cohen's kappa. Construct validity was assessed using the Spearman correlation coefficient between the SCQ and the Charlson Comorbidity Index (CCI), clinician-reported SCQ, quality of life, IBD-related healthcare and productivity costs, prevalence of disability, and IBD disease activity. We assessed responsiveness by correlating changes in the SCQ with changes in healthcare costs, productivity costs, quality of life, and disease activity after 15 months.Results: We included 613 patients. At least fair agreement (κ > 0.20) was found for most comorbidities, but the agreement was slight (κ < 0.20) for stomach disease [κ = 0.19, 95% CI (-0.03; 0.41)], blood disease [κ = 0.02, 95% CI (-0.06; 0.11)], and back pain [κ = 0.18, 95% CI (0.11; 0.25)]. Correlations were found between the SCQ and the clinician-reported SCQ [ρ = 0.60, 95% CI (0.55; 0.66)], CCI [ρ = 0.39, 95% CI (0.31; 0.45)], the prevalence of disability [ρ = 0.23, 95% CI (0.15; 0.32)], and quality of life [ρ = -0.30, 95% CI (-0.37; -0.22)], but not between the SCQ and healthcare or productivity costs or disease activity (|ρ| ⩽ 0.2). A change in the SCQ after 15 months was not correlated with a change in any of the outcomes.Conclusion: The SCQ is a valid tool for measuring comorbidity in IBD patients, but face and content validity should be improved before being used to correct case-mix differences.","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"16 ","pages":"17562848231202159"},"PeriodicalIF":3.4000,"publicationDate":"2023-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/20/10.1177_17562848231202159.PMC10591493.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231202159","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients.

Objectives: We assessed the validity of the SCQ for measuring comorbidities in IBD patients.

Design: Cohort study.

Methods: We assessed the criterion validity of the SCQ for IBD patients by comparing patient-reported and clinician-reported comorbidities (as noted in the electronic health record) of the 13 diseases of the SCQ using Cohen's kappa. Construct validity was assessed using the Spearman correlation coefficient between the SCQ and the Charlson Comorbidity Index (CCI), clinician-reported SCQ, quality of life, IBD-related healthcare and productivity costs, prevalence of disability, and IBD disease activity. We assessed responsiveness by correlating changes in the SCQ with changes in healthcare costs, productivity costs, quality of life, and disease activity after 15 months.

Results: We included 613 patients. At least fair agreement (κ > 0.20) was found for most comorbidities, but the agreement was slight (κ < 0.20) for stomach disease [κ = 0.19, 95% CI (-0.03; 0.41)], blood disease [κ = 0.02, 95% CI (-0.06; 0.11)], and back pain [κ = 0.18, 95% CI (0.11; 0.25)]. Correlations were found between the SCQ and the clinician-reported SCQ [ρ = 0.60, 95% CI (0.55; 0.66)], CCI [ρ = 0.39, 95% CI (0.31; 0.45)], the prevalence of disability [ρ = 0.23, 95% CI (0.15; 0.32)], and quality of life [ρ = -0.30, 95% CI (-0.37; -0.22)], but not between the SCQ and healthcare or productivity costs or disease activity (|ρ| ⩽ 0.2). A change in the SCQ after 15 months was not correlated with a change in any of the outcomes.

Conclusion: The SCQ is a valid tool for measuring comorbidity in IBD patients, but face and content validity should be improved before being used to correct case-mix differences.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

炎症性肠病患者自填合并症问卷的有效性。

背景：国际健康结果测量联合会在比较医疗保健提供者之间炎症性肠病（IBD）治疗的结果时，选择了自我管理的共病问卷（SCQ）来调整病例组合。然而，SCQ尚未被证实可用于IBD患者。目的：我们评估SCQ测量IBD患者合并症的有效性。设计：队列研究。方法：我们通过使用Cohen’s kappa比较患者报告和临床医生报告的13种SCQ疾病的合并症（如电子健康记录中所述），评估SCQ对IBD患者的标准有效性。使用SCQ和Charlson共病指数（CCI）之间的Spearman相关系数、临床医生报告的SCQ、生活质量、IBD相关的医疗保健和生产成本、残疾患病率和IBD疾病活动性来评估结构有效性。我们通过将SCQ的变化与15岁后医疗成本、生产力成本、生活质量和疾病活动的变化相关联来评估反应性月。结果：纳入613例患者。至少公平的协议（κ > 0.20），但一致性很小（κ 结论：SCQ是测量IBD患者共病的有效工具，但在用于校正病例混合差异之前，应提高面孔和内容的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.70

自引率

2.40%

发文量

103

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.